TY - JOUR
T1 - Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen
T2 - A 24-week prospective study
AU - Jena, Anupam
AU - Sachdeva, Ravinder K.
AU - Sharma, Aman
AU - Wanchu, Ajay
PY - 2009/9
Y1 - 2009/9
N2 - Background: Few studies have addressed the issue of adverse drug reactions with non-protease inhibitor (PI)-based antiretroviral therapy (ART) in resource-constrained settings. We studied prospectively the incidence of adverse drug reactions with generic ART among our patients. Methodology: A total of 100 HIV-infected individuals were recruited. Patients received nevirapine (NVP) or efavirenz (EFV) with lamivudine (3TC) and zidovudine (ZDV)/stavudine (d4T). They were followed for 6 months for evidence of adverse drug reactions. Results: The mean CD4 count was 114.09 ± 60.07 cells/mm 3 (range, 12-232 cells/mm 3). Transient gastrointestinal symptoms were most frequent. Fourteen individuals (12 receiving ZDV/d4T, 3TC, NVP and 2 receiving ZDV/d4T, 3TC, EFV) developed skin rash. Among patients receiving NVP, 25.7% developed grade 1 hepatotoxicity. Three patients had numbness in both lower limbs. Among those individuals who received EFV, 32.3% individuals had central nervous system (CNS) symptoms in the form of insomnia, vivid dreams, dizziness, and drowsiness. Conclusion: As the developing world increasingly uses generic ART, the clinician must be constantly vigilant for treatment-related adverse events.
AB - Background: Few studies have addressed the issue of adverse drug reactions with non-protease inhibitor (PI)-based antiretroviral therapy (ART) in resource-constrained settings. We studied prospectively the incidence of adverse drug reactions with generic ART among our patients. Methodology: A total of 100 HIV-infected individuals were recruited. Patients received nevirapine (NVP) or efavirenz (EFV) with lamivudine (3TC) and zidovudine (ZDV)/stavudine (d4T). They were followed for 6 months for evidence of adverse drug reactions. Results: The mean CD4 count was 114.09 ± 60.07 cells/mm 3 (range, 12-232 cells/mm 3). Transient gastrointestinal symptoms were most frequent. Fourteen individuals (12 receiving ZDV/d4T, 3TC, NVP and 2 receiving ZDV/d4T, 3TC, EFV) developed skin rash. Among patients receiving NVP, 25.7% developed grade 1 hepatotoxicity. Three patients had numbness in both lower limbs. Among those individuals who received EFV, 32.3% individuals had central nervous system (CNS) symptoms in the form of insomnia, vivid dreams, dizziness, and drowsiness. Conclusion: As the developing world increasingly uses generic ART, the clinician must be constantly vigilant for treatment-related adverse events.
KW - AIDS
KW - HIV
KW - adverse drug reaction
KW - anti-retroviral therapy
KW - nonnucleoside reverse transcriptase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=75349090739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75349090739&partnerID=8YFLogxK
U2 - 10.1177/1545109709343967
DO - 10.1177/1545109709343967
M3 - Article
C2 - 19721097
AN - SCOPUS:75349090739
SN - 1545-1097
VL - 8
SP - 318
EP - 322
JO - Journal of the International Association of Physicians in AIDS Care
JF - Journal of the International Association of Physicians in AIDS Care
IS - 5
ER -